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Microdialysis during i.v. drug self-administration (SA) have implicated nucleus accumbens (NAc) shell DA
in cocaine and heroin reinforcement. However, this correlative evidence has not been yet substantiated
by experimental evidence obtained by studying the effect of selective manipulation of NAc shell DA
transmission on cocaine and heroin SA. In order to investigate this issue, DA D1a receptor (D1aR)
expression was impaired in the NAc shell and core by locally infusing lentiviral vectors (LV) expressing
speciﬁc D1aR-siRNAs (LV-siRNAs). Control rats were infused in the same areas with LV expressing GFP.
Fifteen days later, rats were trained to acquire i.v. cocaine or heroin self-administration (SA). At the end of
behavioral experiments, in order to evaluate the effect of LV-siRNA on D1aR expression, rats were
challenged with amphetamine and the brains were processed for immunohistochemical detection of c-
Fos and D1aR. Control rats acquired i.v. cocaine and heroin SA. Infusion of LV-siRNAs in the medial NAc
shell reduced D1aR density and the number of c-Fos positive nuclei in the NAc shell, while sparing the
core, and prevented the acquisition of cocaine, but not heroin SA. In turn, LV-siRNAs infusion in the core
reduced D1aR density and the number of c-Fos positive nuclei in the same area, while sparing the shell,
and failed to affect acquisition of cocaine. The differential effect of LV impairment of NAc shell D1aR on
cocaine and heroin SA indicates that NAc shell DA acting on D1aR speciﬁcally mediates cocaine
reinforcement.
1. Introduction
A large body of evidence indicates that dopamine (DA) is the
main neurochemical substrate of cocaine reinforcing properties.
Early experimental studies by Ettenberg et al. (1982) showed that
systemic administration of DA receptor antagonists elicits a
compensatory increase of intravenous (i.v.) cocaine self-
administration (SA) in fully trained rats, thus mimicking the ef-
fect of non-reinforcement. In turn, discrete lesions of DA terminals
by 6-OHDA point to the nucleus accumbens (NAc) as the DA pro-
jection area responsible for cocaine reinforcement (Pettit et al.,
1984; Roberts et al., 1980). Studies on the effect of systemic and
local intracerebral infusion of selective D1 antagonists (Caine et al.,
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1995; Koob et al., 1987; Maldonado et al., 1993) on i.v. cocaine SA
indicate a speciﬁc role of NAc DA D1 receptors.
Consistent with a role of NAc DA in cocaine behavioral effects,
brain microdialysis studies have shown that response non-
contingent administration of cocaine, amphetamine and most
drugs of abuse, preferentially increases extracellular DA in the NAc,
as compared to the dorsal caudate-putamen (Carboni et al.,1989; Di
Chiara and Imperato, 1988). Microdialysis studies, in addition, have
shown that cocaine increases extracellular DA in the NAc even after
i.v. self-administration (Di Ciano et al., 1995; Pettit and Justice,1989,
1991; Wise et al., 1995; Lecca et al., 2007a). Moreover, preferential
stimulation of DA transmission in the ventral striatum by
amphetamine has been demonstrated in humans by Positron
Emission Tomography of [11C] raclopride binding (Drevets
et al.,1999, 2001; Leyton et al., 2002; Martinez et al., 2003).
Anatomical studies have shown that the NAc is heterogenous
with regards to its cytoarchitecture, connections and distribution of
neurotransmitters, their enzymes and receptors. Thus, a medio-
ventral part, the shell, and a dorso-lateral part, the core, have
been distinguished (Groenewegen et al., 1999; Heimer et al., 1997).
These two subdivisions, in turn, have been assigned different
functions in behavior motivated by food and drugs of abuse (Corbit
et al., 2001, Corbit and Balleine, 2011; Di Chiara, 2002; Di Chiara
et al., 2004; Parkinson et al., 2002).
As far as DA transmission is concerned, cocaine, like other drugs
of abuse, preferentially increases extracellular DA in the NAc shell
as compared to the core (Di Chiara, 2002). This preferential action
has been initially documented by microdialysis studies in acutely
experimenter-administered rats (Aragona et al., 2008; Pontieri
et al., 1995) and later demonstrated in rats during acquisition of
i.v. cocaine SA (Lecca et al., 2007a).
The NAc shell, rather than the core, is also the area from which
robust SA can be consistently obtained after response-contingent
intracerebral infusion (Ikemoto, 2003; Rodd-Henricks et al.,
2002), which, in turn, explains previous negative results obtained
by infusions that did not speciﬁcally target the shell (Goeders and
Smith, 1983).
The evidence presented above is suggestive, but, in order to
demonstrate that NAc shell and core DA plays a differential role in
cocaine reinforcement, a study of the effect of local impairment of
DA transmission on i.v. cocaine SA is required. To our knowledge,
four studies have directly compared the effect of impairment of DA
transmission in the NAc shell and core on cocaine reinforcement.
While in two studies no clear-cut differences were obtained be-
tween the two NAc subdivisions (Bachtell et al., 2005; Bari and
Pierce, 2005), in the other two studies, the differences obtained
have led to opposite conclusions (Di Ciano, 2008; Veeneman et al.,
2012). These discrepancies and inconsistencies might result from
the use of local intracerebral infusion of DA antagonists as a tool to
manipulate DA transmission in the NAc shell and core. These drugs
are highly lipophilic and rapidly diffuse out of their intracerebral
target area, particularly after repeated administration. These difﬁ-
culties call for the use of other means to impair DA transmission.
In recent years, RNA interference (RNAi), an evolutionary
conservedmechanism of genome protection against viral infections
and mutations (Hamilton and Baulcombe, 1999; Jensen et al., 1999;
Sharp and Zamore, 2000), has been used to silence protein
expression (Hannon and Rossi, 2004). RNAi is triggered in
eukaryotic cells by double-stranded RNAs having 19e21 nucleo-
tides (short interfering RNA, siRNA; Fire et al., 1998), which, when
recognized as aberrant, induce a polyenzymatic process leading to
degradation of homologous mRNAs (Hannon, 2002). For in vivo
application, viral mediated expression of siRNAs, which takes place
a few days after transduction (Bahi and Dreyer, 2012; Ortiz et al.,
2010), allows stable long term RNAi, thus silencing the expression
of the relative genes (Bahi et al., 2004, 2005; Bahi and Dreyer, 2012;
Ortiz et al., 2010; Scherr et al., 2003; Van den Haute et al., 2003).
Viral mediated silencing of targeted proteins offers higher temporal
(RNAi starts right after transduction of targeted cells) and spatial
control (inoculation of deﬁned volumes and concentrations of viral
vectors restricts silencing to targeted areas) of manipulations,
compared to conventional knockout or pharmacological strategies.
D1a (D1aR), rather than D1b receptors, are largely prevalent in
striatal areas (Levey et al., 1993; Luedtke et al., 1999), including NAc
(Muly et al., 2010). Therefore in the present study, D1aR silencing by
lentiviral mediated expression of speciﬁc siRNA in discrete regions
of rat NAc shell or core, was utilized to investigate the role of D1aR
in cocaine reinforcement using an i.v. cocaine SA paradigm.
In order to test the speciﬁcity of the effect of D1aR silencing on
the acquisition of cocaine reinforcement, the effect of the same
manipulation on the acquisition of i.v. heroin SA was investigated.
Heroin also increases dialysate DA preferentially in the NAc shell
(Lecca et al., 2007b). Moreover, systemic ﬂupentixol, a DA D2/D1
receptor antagonist, differentially affects responding for i.v. cocaine
and heroin SA. At low doses it selectively increases responding for
cocaine without affecting responding for heroin, while at higher
doses, it reduces responding for both drugs (Ettenberg et al., 1982).
These observations have been interpreted to mean that low doses
of ﬂupentixol selectively impair cocaine reinforcement, while
higher doses exert a general effect on motivation and on its
expression into action (Ettenberg et al., 1982). Given these pre-
mises, manipulation of DA D1aR expression by RNAi in the NAc
shell versus core was utilized to investigate the role of DA in these
two NAc subdivisions in cocaine reinforcement.
2. Materials and methods
2.1. Animals
Male SpragueeDawley rats (Harlan, Italy), weighing 250e275 g at the beginning
of experimental procedures, were housed four per cage with ad libitum food and
water, under constant lightedark cycle (on 08:00 A.M., off 08:00 P.M.), temperature
(22 C) and humidity (60%). After catheter implantation and lentiviral stereotaxic
injections, rats were individually housed in plastic cages (30  20  20 cm) in the
same environmental conditions. During recovery (two weeks), rats were handled,
treated with 0.1 ml of gentamicin (40 mg/ml, i.v.), and their catheters were daily
ﬂushed with heparinized saline (heparin 25 IU in 0.9% sterile saline).
Self-administration (SA) sessions were performed after recovery, during the
light phase, between 10:00 A.M. and 5:00 P.M. and, after each experimental session,
rats were returned to their home cages, where a daily ration of 20 g of food was
made available.
All experimental procedures met the guidelines and protocols approved by the
European Parliament and the Council of the European Union (directive 2010/63/EU,
L 276/33 20/10/2010) and approved by the Ethical Committee for Animal Use and
Care of the University of Cagliari. All efforts have been made to minimize suffering
and the numbers of animals used.
2.2. Drugs
Cocaine hydrochloride (McFarlan Smith, Edinburgh, Scotland, UK) and heroin
hydrochloride (NIDA, Research Triangle Park, NC, USA)were dissolved daily in sterile
saline (0.9%), and drug concentration was adjusted daily according to the weight of
the rats. Amphetamine sulfate (Sigma, Milan, Italy) was dissolved in sterile saline
(0.9%) and administered subcutaneously. All reagents were obtained from local
suppliers and were of analytical grade.
2.3. Construction and validation of LV-Drd1a-siRNAs
The construction of Drd1a-siRNA expressing lentiviruses has been described
previously in detail (Bahi and Dreyer, 2012; Ortiz et al., 2010). In brief, three 19-
nucleotide Drd1a-siRNA sequences were added to the U6 promoter by PCR. The
PCR product was digested with BamHI/XhoI and then ligated into the pTK431 pre-
viously digested with the same enzymes. Preparation of lentiviral vectors was
initiated by triple transfection of HEK293Tcells by calcium phosphatemethod, using
pTK431 together with pDeltaNRF and pMDG-VSV. Cells were harvested 72 h later
and viruses were concentrated from the supernatant by ultracentrifugation. Vectors
were resuspended in PBS-BSA and stored at 80 C until use (Bahi, 2013; Bahi and
Dreyer, 2013). The three distinct Drd1a-siRNA sequences were successfully used to
knock-down the expression Drd1a mRNA in the NAc (Bahi and Dreyer, 2012) and
proteins in the hippocampus (Ortiz et al., 2010).
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2.4. Catheter implant and lentivirus inoculation
Rats were anaesthetized with Equitesin (0.97 g pentobarbital, 4.25 g chloral
hydrate, 2.1 g MgSO4, 42.8 ml propylene glycol, 11.5 ml 90% ethanol/100 ml; 5 ml/kg
i.p.) and implanted into the right jugular veinwith a catheter (Medical-grade tubing;
Silastic, Dow Corning Corporation, Midland, MI, USA) ﬁxed in the middle scapular
region by a polypropylene mesh (Evolution, BULEV, weight 48 g/mq, Dipromed,
Italy). This ensured stable ﬁxation, rapid tissue integration and reduced foreign body
reaction. During the same surgical procedure, rats underwent bilateral stereotaxic
inoculation of lentiviral vectors in the NAc shell or core compartments; LV-Drd1a-
siRNA1, LV-Drd1a-siRNA2 and LV-Drd1a-siRNA3 concentrate stocks were mixed
right before inoculation, and the LV-siRNAs mix and LV-GFP vectors were kept in ice
at 0 C until use. Stereotaxic inoculation was made using a 33-gauge tip needle
connected by a polyethylene tubing to a 10-mL Hamilton syringe, driven by an
infusion pump (Basile, Milan, Italy).
For cocaine SA, lentiviral vectors were inoculated using two different experi-
mental protocols (Experiment I and Experiment II). For Experiment I, 4 ml of vector
solution (LV-siRNAs or LV-GFP vectors) were bilaterally inoculated by a single in-
jection in the NAc shell or core of 40 rats, using the following coordinates: i) NAc
shell: AP þ1.7 mm; L ±1.1 mm, from bregma; V 7.7 mm from dura, in LV-siRNAs
shell and LV-GFP shell groups; ii) NAc core: A þ1.5 mm; L ±1.8 mm, V 7.0 mm,
in LV-siRNAs core and LV-GFP core groups, according to the Paxinos and Watson
Atlas (2005). For Experiment II, 28 rats were bilaterally inoculated in two different
sites in the NAc shell or core compartments (rostro-caudal interval of 500 mm), and
for each inoculation the volume was 2 ml. The following coordinates were used: i)
NAc shell, caudal inoculation: Aþ1.7; L ±1,1; V7.7 mm; rostral inoculation, Aþ2.2;
L ±0.8; V 7.2 mm, for LV-siRNAs shell and LV-GFP shell groups; ii) NAc core, caudal
inoculation: A þ1.5; L ±1.8; V 7.0 mm; rostral inoculation: A þ2.0; L ±1.6;
V 6.4 mm, for LV-siRNAs core and LV-GFP core groups.
For heroin SA (Exp. III), 4 ml of vector solution (LV-siRNAs or LV-GFP vectors)
were bilaterally inoculated by a single injection in the NAc shell of 12 rats/group
using the following coordinates: AP þ1.7 mm; L ±1.1 mm, measured from bregma;
V 7.7 mm from dura, in LV-siRNAs shell and LV-GFP shell groups, according to the
Paxinos and Watson Atlas (2005).
The rate of infusion was 0.2 ml/min; the cannula was maintained in place for
further 10 min after inoculation and then gradually withdrawn in order to allow a
proper vector diffusion into the injected brain areas and to prevent their backﬂow
through the needle track.
2.5. Cocaine self-administration
After 15 days of recovery from surgical procedures, which is sufﬁcient to reach a
maximal degree of D1aR silencing in vivo (Ortiz et al., 2010), rats were trained to
self-administer cocaine intravenously (unit doses, 0.25mg/kg in 24 ml) in single daily
1-h sessions for 5 days/week, under ﬁxed ratio schedule 1 (FR-1, 1 nose-poke for 1
infusion), which was then increased to FR-5 (5 nose-pokes for 1 infusion) starting
from the 15th session in each experiment. At this point, in at least one experimental
group, rats reached the criterion for acquisition (set at 85% of responses on the active
hole), keeping a stable pattern over three sessions. Starting from the 23rd (Experi-
ment I) or the 34th session (Experiment II), rats were switched to extinction by
substituting the cocaine solutionwith saline (Fig. 1). Each SA sessionwas carried out
in chambers (31  26  33 cm) housed in sound proof boxes (Coulbourn In-
struments, Allentown, NJ, USA) and provided with two nose-poke holes, one active
and the other one inactive, placed in the short walls of the cage 2 cm from the ﬂoor. A
yellow/green light was placed over the active hole, and a red light over the inactive
one, as discriminative stimuli. Prior to each daily session, the jugular catheter was
ﬂushed with 0.1 ml of sterile saline, and rats were connected to the infusion system
and placed into the Skinner box.
A computerized program (Graphic State 2 software, Coulbourn instrument, PA,
USA) controlled each phase of SA session, with: 1) ready state, involving activation of
the pump for 2 s to ﬁll up the jugular catheter with cocaine solution (dead volume,
50-ml); 2) cocaine available state, involving FR-1 or FR-5 nose poking in the active
hole; 3) infusion state, resulting in 2-s i.v. cocaine injection (0.25 mg/kg in 24-ml); 4)
20-s time-out state, during which further nose-pokes were recorded, but did not
result in additional infusions. During the time-out, a scheduled house light was
turned on, and both active and inactive holes were red lighted. After the time-out,
cocaine availability was once again indicated by turning on the yellow/green light
in the active hole. Inactive nose-pokes were also recorded. At the end of the session,
all light stimuli were turned off, the rats' catheter was ﬂushed with 0.1 ml of hep-
arinized saline, and the animals were returned to their home cages. During the
extinction phase, cocaine solutionwas replacedwith saline, so that FR-5 active nose-
poking during each SA session resulted in i.v. saline injections, under the same test
conditions of previous cocaine SA sessions.
2.6. Heroin self-administration
In Exp. III, after recovery (15 days), rats were trained to i.v. heroin (0.05 mg/kg,
48 ml/4 s) SA in single daily 1-h sessions for 5 days/week under FR-1 schedule, which
was then increased to FR-5 on the 11th session, once rats had reached the criterion
for acquisition. Starting from the 26th session, rats underwent extinction and heroin
solution was substituted by saline (Fig. 1). Each heroin SA session was carried out in
the same chambers and environmental conditions described for cocaine. During
extinction, heroin solutionwas replaced with saline, so that FR-5 active nose-poking
resulted in i.v. saline injections (48 ml/4 s).
2.7. Immunohistochemistry
In all experiments, the day after the last SA session, rats were challenged with
saline or amphetamine (5 mg/kg, s.c.). Two hours after challenge rats were deeply
anaesthetized with Equitesin (5 ml/kg, i.p.) and transcardially perfused with 100 ml
of ice-cold saline, followed by 250 ml of ice-cold 4% paraformaldehyde (PFA) dis-
solved in 0.1 M sodium phosphate buffer, pH 7.4.
Fig. 1. Timeline for experimental setting. Time of recovery (days), phases of i.v. cocaine (Exp. I and II) and heroin (Exp. III) SA (sessions), extinction (sessions) and amphetamine
challenge are shown. Arrowheads indicate lentivirus inoculations.
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Brains were removed and post-ﬁxed overnight with 4% PFA at 4 C. Serial cor-
onal sections, which included NAc, were cut on a Vibratome (40-mm thickness;
VT1000 S, Leica Microsystems Germany). Six sets of 6 sections, separated by a
minimum of 240 mm, were collected for each animal so that adjacent sets of
equivalent anteroposterior level could be used for immunostaining of D1aR, c-Fos
protein and tyrosine hydroxylase (TH) and for qualitative analysis of GFP expression.
Free ﬂoating sections were incubated with the primary antibodies (D1aR,
1:1000, monoclonal anti-D1aR IgG raised in mouse; c-Fos,1:2000, polyclonal anti-c-
Fos IgG raised in sheep;Millipore, USA; TH,1:1000, monoclonal anti-TH IgG raised in
mouse, Sigma Aldrich, Italy). The reaction was visualized using biotinylated sec-
ondary antisera (1:500, donkey anti-mouse IgG biotin-SP-conjugate; 1:700, donkey
anti-sheep IgG biotin-SP-conjugate, Jackson ImmunoResearch, UK) and standard
avidinebiotinehorseradish peroxidase technique (ABC-elite kit, Vector Labs, UK,
and Fast-DAB solution, SigmaeAldrich, Italy). After this, sections were mounted on
positively charged microscope slides, dehydrated, coverslipped using Eukitt
mounting medium (Fluka, SigmaeAldrich, Italy) and allowed to dry overnight.
Images were acquired with a Zeiss AxioScopeA1 microscope equipped with
20/0.45 and 40/0.65 Zeiss N-Acroplan objectives, and a high resolution scanner
for medical slides (Super Coolscan 9000ED, Nikon) set at 4000 dpi.
D1aR immunoreactivity (D1-IR) in the target area (NAc core and/or shell) was
quantiﬁed as optical density, corrected for cortex signal meant as background, in
images acquired by the high resolution scanner. D1-IR in the region of interest (ROI,
inoculated area) was then expressed as percentage of the overall optical density of
the related target area for each section analyzed. In adjacent sections, c-Fos
immunoreactivity (c-Fos-IR) was quantiﬁed as counts/ﬁeld of c-Fos positive nuclei in
the ROI. Number of c-Fos positive nuclei was determined in the inoculated region of
the NAc core and hell, in images acquired using 20 objective, by applying the
“entropy threshold” and “analyze-particles” tools of Image J software (U.S. National
Institutes of Health, USA) in a counting ﬁeld of 500-mm diameter.
GFP autoﬂuorescence was directly detected in a set of six sections for each rat
inoculated with LV-GFP. Sections were rinsed in TrismaeHCl buffered solution
(50 mM, pH 7.4), mounted on positively chargedmicroscope slides and coverslipped
with Vectashield mounting medium (Vector Labs, UK). Images obtained with an
epiﬂuorescence microscope (Axio Scope. A1, Zeiss, Germany) using 20 and 40
objectives were acquired with a digital camera (1.4 MPixels, Inﬁnity 3e1, Lumenera,
Canada).
2.8. Data analysis
Statistical analysis was carried out by Statistica 8 (Stat Soft Inc, Tulsa, OK, US).
2.8.1. Self-administration
A total of 8 rats each were excluded from Experiment I and Experiment II
respectively, due to catheter leakage during cocaine SA or incorrect intracerebral
virus infusion, as indicated by immunohistochemical analysis. For the same reasons,
5 rats were excluded from Experiment III. The data recorded from these animals
were excluded from analysis. Therefore the size of the analyzed and plotted datawas
derived from 8 rats for each group in Experiment I, 5 for Experiment II and 9e10 for
Experiment III.
Nose poking behavior during each daily 1-h cocaine SA session and during
extinction was analyzed by four-way ANOVA, with group (LV-siRNAs vs LV-GFP-
controls), area (NAc shell vs core) and cumulative nose-pokes (active vs inactive) as
between-subject factors, and session as repeated measure.
Cocaine intake and number of infusions were analyzed by three-way ANOVA,
with group (LV-siRNAs vs LV-GFP-controls) and area (NAc shell vs core) as between-
subject factors, and time as repeated measure of i) daily infusions and ii) weekly
cocaine intake.
Nose poking behavior during each daily 1-h heroin SA sessions and extinction
was analyzed by three-way ANOVA, with group (LV-siRNAs vs LV-GFP-controls) and
cumulative nose-pokes (active vs inactive) as between-subject factors, and session as
repeated measure.
Heroin intake and number of infusions were analyzed by two-way ANOVA, with
group (LV-siRNAs vs LV-GFP-controls) as between-subject factors, and with time as
repeated measure of i) daily infusions and ii) weekly heroin intake.
If signiﬁcant effects or interactions were obtained with ANOVA, multiple pair
wise contrasts were made by Tukey's HSD or Fisher's LSD post-hoc test, as reported
in each experiment. Signiﬁcance was set at P < 0.05.
2.8.2. Immunohistochemistry
D1-IR, quantiﬁed as percent (%) of overall optical density of the target area, was
analyzed by a three-way ANOVA, with group (LV-siRNAs vs LV-GFP), target area (NAc
shell vs core) and ROI (NAc shell vs core) as factors in Experiment I and II, and by one-
way ANOVA with group (LV-siRNAs vs LV-GFP) factor in Experiment III. c-Fos-IR,
quantiﬁed as counts/ﬁeld of c-Fos-positive nuclei in the ROI, was analyzed by a four-
way ANOVA with group (LV-siRNAs vs LV-GFP), target area (NAc shell vs core), ROI
(NAc shell vs core) and challenge (saline vs amphetamine, 5 mg/kg) as between-
subject factors in Experiment I, three-way ANOVA, with group (LV-siRNAs vs LV-
GFP), target area (NAc shell vs core), ROI (NAc shell vs core) as between-subject
factors in Experiment II, and one-way ANOVA with group (LV-siRNAs vs LV-GFP) as
between subject factors in Experiment III.
If signiﬁcant effects or interaction were found with ANOVA, Tukey's HSD post-
hoc test was then applied with signiﬁcance set at P < 0.05.
3. Results
3.1. Experiment I
3.1.1. Cocaine self-administration
In Experiment I, the effect of bilateral infusion of 4-ml lentiviral
vectors in the NAc shell (LV-siRNAs shell and LV-GFP shell groups)
or core (LV-siRNAs core and LV-GFP core groups) on intravenous
(i.v.) cocaine SA was evaluated. Rats were trained to acquire 1-h
daily i.v. cocaine SA (unit dose 0.25 mg/kg, 5 day/week) for 15
sessions under FR-1 and for 7 sessions under FR-5 schedules of
responding, followed by 10 sessions of extinction (saline, 24 ml/
infusion).
3.1.1.1. Responding. Fig. 2 shows cumulative active and inactive
nose-pokes performed by the LV-GFP and LV-siRNAs shell groups
on panel A, and the LV-GFP and LV-siRNAs core groups on panel B,
throughout the cocaine SA (FR-1: 1ste15th sessions, FR-5:
16the22nd sessions) and extinction (FR-5: 23rde32nd sessions)
phases.
Four-way ANOVA with nose-pokes (active and inactive), group
(LV-GFP and LV-siRNAs), area (shell and core) and session (days) as
factors, showed a main effect of nose-pokes (active vs inactive;
F1,56 ¼ 96.01, P ¼ 0.000001) and session (F31,1736 ¼ 35.19,
P ¼ 0.000001) and signiﬁcant group  session (F31,1736 ¼ 2.13,
P ¼ 0.0003), nose-pokes  session (F31,1736 ¼ 32.43, P ¼ 0.000001),
group  area  session (F31,1736 ¼ 2.94, P ¼ 0.00001) and
group  area  nose poking  session (F31,1736 ¼ 2.30, P ¼ 0.00007)
interactions. The LV-GFP shell rats acquired cocaine SA behavior
under FR-1 schedule during the second week and further increased
active nose poking under FR-5 schedule (P < 0.05 for active nose
poking compared to inactive, Tukey's HSD post-hoc test), whereas
the LV-siRNAs shell rats showed a delayed acquisition under FR-1
schedule, and lower active nose poking under FR-5 schedule, as
compared to the LV-GFP shell controls (higher LV-GFP shell active
nose poking compared to LV-siRNAs shell from the 16th to the 22nd
session, P < 0.05 Tukey's HSD post-hoc test). During extinction,
substitution of cocaine with saline resulted in a marked fall of
responding on the active hole during the ﬁrst saline session itself in
the LV-GFP shell rats, while the LV-siRNAs shell rats exhibited a
pattern not different from previous FR-5 SA sessions, with only a
slight reduction in nose poking during the last days (P < 0.05 for
active nose-poking compared to inactive, Tukey's HSD post-hoc
test) (Fig. 2A).
Infusion of LV-siRNAs in the NAc core did not modify cocaine SA
(Fig. 2B); active nose-pokes performed by the LV-siRNAs core rats
were similar to those performed by the LV-GFP core control rats.
Both the LV-GFP core and LV-siRNAs core groups rapidly acquired
cocaine SA under FR-1 schedule during the 2nd week, and signiﬁ-
cantly increased their nose poking activity under FR-5 schedule
(higher active nose-poking compared to inactive, P < 0.05 Tukey's
HSD post-hoc test). Moreover as seen for LV-GFP shell group, during
the extinction phase both core groups quickly reduced their active
nose poking behavior (Fig. 2B).
3.1.1.2. Cocaine intake. Three-way ANOVA, with group, area and
session as factors, was applied to daily infusions of cocaine or sa-
line. It showed a main effect of session (F31,868 ¼ 26.72,
P ¼ 0.000001) and a group  session (F31,868 ¼ 2.48, P ¼ 0.000017)
and group  area  session (F31,868 ¼ 1.85, P ¼ 0.003) interactions.
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As shown in Fig. 2C, the LV-GFP shell rats rapidly increased in-
fusions of cocaine over days during the 2nd week (P < 0.05 vs 1st
day, Tukey's HSD post-hoc test), while the LV-siRNAs shell rats did
not show any increase. On the other hand, both the LV-siRNAs core
and LV-GFP core groups showed an increase starting from the 2nd
week (P < 0.05 vs 1st day, Tukey's HSD post-hoc test. Fig. 2D). The
number of cocaine infusions during the 16th session was affected
by switching operant ratio schedule from FR-1 to FR-5.
Three-way ANOVA applied to cocaine intake, expressed as
weekly means under FR-1 and FR-5 schedules of responding,
showed similar results, with main effect for week (F3,84 ¼ 36.24,
P ¼ 0.000001), characterized by increase of weekly cocaine intake
starting from the 2nd week in all experimental groups, except for
the LV-siRNAs shell group (P < 0.05 vs 1st week, Tukey's HSD post-
hoc test, Table 1).
3.1.2. Immunohistochemistry
3.1.2.1. GFP expression. In vivo transfection was evaluated by green
ﬂuorescent protein (GFP) expression, detected in a set of six sec-
tions in the LV-GFP rats. In Experiment I, 4 ml of LV-GFP, infused
either in the NAc shell or core, spread z350 mm rostrally and
caudally from the inoculation site. Fig. 3 shows the sites of infusion
(panels A and B) and GFP expression in the NAc shell and core after
infusion of 4-ml Lenti-GFP (panels E and F).
3.1.2.2. TH expression. Integrity of presynaptic dopaminergic ﬁbers
in the NAc core and shell of silenced subjects was evaluated by
immunohistochemical staining of TH. In fact, immunoreactivity for
TH was not modiﬁed in the inoculated areas as indicated in Fig. 3
(panels A1-A4).
3.1.2.3. D1aR density and c-Fos expression. D1aR expression was
quantiﬁed as percentage change of ROI optical density, compared to
the overall optical density of the corresponding target area, while
as an indirect measure of D1aR activation in virus infused regions,
basal and amphetamine-induced c-Fos expression was quantiﬁed
as counts/ﬁeld of c-Fos positive nuclei.
D1aR and c-Fos immunoreactivity in the NAc shell and core of
representative rats from Experiment I are shown in Fig. 4. Column B
shows D1-IR, column C represents the pattern of nuclear c-Fos-IR
distribution, while columns D and E are 20 magniﬁcations of
nuclear c-Fos-IR of the selected rectangular regions indicated in
column C, relative to dorsal core and medial shell respectively.
As illustrated in column D of Fig. 4 (lines 1 and 2), c-Fos
expression in the core of the LV-siRNAs shell rats was similar to that
Fig. 2. Experiment I: Cumulative responses and drug intake during intravenous cocaine self-administration and extinction. Cumulative responses (A and B): results are expressed as
mean ± SEM of cumulative active (ﬁlled symbols) and inactive (open symbols) nose-pokes performed by LV-GFP shell (circles) and LV-siRNAs shell (triangles) groups (panel A) and
by LV-GFP core (squares) and LV-siRNAs core (rhombs) groups (panel B) under FR-1 (1ste15th sessions) and FR-5 (16the22nd sessions) 1-h daily i.v. SA of cocaine (0.25 mg/kg), or
saline (24 ml per bolus) during extinction phase (23rde32nd sessions). n ¼ 8 rats for each group. *: P < 0.05 vs inactive nose-pokes intergroup; : P < 0.05 vs LV-siRNAs shell. ANOVA
followed by Tukey's HSD post-hoc test. Drug intake (C and D): Intake data are expressed as mg/kg of cocaine, self-administered during sessions (ﬁlled symbols: 1ste22nd sessions),
as indicated on left Y-axis, as well as number of cocaine (ﬁlled symbols: 1ste22nd sessions) or saline (open symbols: 23rde32nd days) injections received during each SA phases, as
indicated on the right Y-axis. LV-GFP shell rats (circles) and LV-siRNAs shell rats (triangles) are shown in panel C; LV-GFP core rats (squares) and LV-siRNAs core rats (rhombs) are
shown in panel D, n ¼ 8 rats for each group. *: P < 0.05 vs session 1 within group; ANOVA followed by Tukey's HSD post-hoc test.
Table 1
Experiment I. Mean ± SEM of weekly cocaine intake per session (mg/kg) in LV-GFP
and LV-siRNAs shell and core groups under FR-1 (1ste3rd week) and FR-5 (4th
week) i.v. cocaine SA. n ¼ 8 rats per group.*: P < 0.05 vs 1st week; : P < 0.05 vs
respective GFP control group. ANOVA followed by Tukey's HSD post-hoc test.
SA phases: Groups:
LV-GFP
shell
LV-siRNAs
shell
LV-GFP
core
LV-siRNAs
core
FR-1
1st week 1.6 ± 0.6 1.3 ± 0.8 1.9 ± 0.5 2.0 ± 0.5
2nd week 6.2 ± 2.1* 2.3 ± 1.0 5.8 ± 1.4* 6.0 ± 1.3*
3rd week 8.6 ± 1.5* 4.2 ± 1.1 7.5 ± 1.3* 7.2 ± 1.3*
FR-5
4th week 7.8 ± 1.2* 3.1 ± 1.1 6.9 ± 1.3* 6.2 ± 1.2*
*: P < 0.05 vs 1st week.
: P < 0.05 vs respective GFP control group.
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Fig. 3. Sites of vector inoculation and GFP expression. Panels A and B represent a schematic drawing of sites of LV-siRNAs or LV-GFP vectors inoculation (gray vertical bars) in the
NAc shell (A) and core (B), according to Paxinos and Watson (2005). Panels C to F illustrate GFP expression induced by inoculation of 2 ml (C and D; relative to experiment II) or 4 ml (E
and F relative to experiments I and III) of LV-GFP vectors in the shell (upper panels) or in the core (lower panels) of NAc. Images have been acquired by a Zeiss AxioScopeA1
epiﬂuorescent microscope using a 10 magniﬁcation objective, Abbreviations: ac, anterior commissure; co, NAc core; sh, NAc shell. Scale bar is 500 mm.
Fig. 4. Experiment I: TH, D1aR and c-Fos expression in the NAc of LV-GFP and LV-siRNAs rats. Columns A, B and C show respectively TH and D1aR immunoreactivity and pattern of
induction of nuclear c-Fos immunoreactivity, in representative LV-GFP shell (row 1), LV-siRNAs shell (row 2), LV-GFP core (row 3) and LV-siRNAs core (row 4) rats. Microphotographs
were acquired by a Nikon Cool Scan 9000ED with a scanning resolution of 4000 dpi, scale bar is 500 mm. Columns D and E show magniﬁcations (20) of c-Fos immunoreactivity of
dorsal core (D) and medial shell (E) in the regions of interest (rectangles) represented in column C. Microphotographs have been acquired by a Zeiss AxioScopeA1 microscope with a
20 magniﬁcation objective, scale bar is 100 mm.
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of the LV-GFP shell rats, whereas the LV-siRNAs shell rats showed a
reduction of c-Fos positive nuclei (column E) in the NAc shell,
particularly in the medial portion compared to the LV-GFP shell
control group. Moreover, as illustrated in column B, the same
medial portion of the NAc shell of the LV-siRNAs rats showed a
decreased D1-IR. Similarly, as shown in lines 3 and 4, sites of
inoculation in the NAc core showed lower density of c-Fos positive
nuclei and lower D1-IR in the LV-siRNAs core compared to the LV-
GFP control rats. In a few animals this reduction in D1-IR was also
detectable in regions adjacent to the shell or core boundaries,
suggesting that excessive spreading of LV-siRNAs vectors may occur
with 4 ml of solution.
Fig. 5 shows percentage changes of D1-IR in the inoculated
areas. Three-way ANOVA among group, area and ROI factors
showed main effect of group (F1,62 ¼ 44.99, P ¼ 0.000001) factor.
Furthermore, there were signiﬁcant area  ROI (F1,62 ¼ 34.00,
P ¼ 0.000001) and group  area  ROI (F1,62 ¼ 55.30, P ¼ 0.000001)
interactions, in accordance with a reduction of D1-IR in the inoc-
ulated area detectable in both the LV-siRNAs groups compared to
their respective LV-GFP controls. As shown in panel 5A, D1-IR was
signiﬁcantly reduced in the NAc shell of the LV-siRNAs shell rats
(79.7%± 0.9) compared to the respective LV-GFP shell control group
(105.1% ± 4.3; P < 0.05, Tukey's HSD post-hoc test), while no
changes were found in the NAc core in both the LV-siRNAs and LV-
GFP shell rats. On the other hand, as shown in Fig. 5B, D1-IR was
signiﬁcantly reduced in the NAc core of the LV-siRNAs core rats
(76.7% ± 2.8) compared to the respective LV-GFP core control group
(108.9% ± 3.4; P < 0.05, Tukey's HSD post-hoc test), while no
changes were found in the NAc shell in both the LV-siRNAs and LV-
GFP core rats.
Fig. 5 also shows changes in expression of c-Fos positive nuclei,
induced by amphetamine challenge (5 mg/kg, i.p.) and measured in
the NAc shell and core of each experimental group. Four-way
ANOVA among challenge, group, area and ROI factors showed
main effects of challenge (F1,54 ¼ 181.02, P ¼ 0.000001) and group
(F1,54 ¼ 6.30, P ¼ 0.01) factors on c-Fos expression. Furthermore,
there were signiﬁcant group  area  ROI (F1,54 ¼ 7.67, P ¼ 0.008)
and challenge  group  area  ROI (F1,54 ¼ 8.71, P ¼ 0.005) in-
teractions, in accordance with a greater expression of c-Fos positive
nuclei elicited by amphetamine challenge in all groups and ROIs,
Fig. 5. Experiment I: Bar charts representing changes in D1aR immunoreactivity and c-Fos expression in the Nac shell and core of LV-GFP and LV-siRNA rats. Panels A and B show
optical density (OD) of D1-IR in the inoculated regions, expressed as percentage of the overall OD of corresponding shell or core areas. Values are expressed as means ± SEM of %OD.
Panels C and D show counts of c-Fos-positive nuclei/ﬁeld in the inoculated regions, in amphetamine (5 mg/kg) or saline (1 ml/kg) challenged rats. Values are expressed as
means ± SEM of positive nuclei/ﬁeld. *: P < 0.05 vs respective saline treated group. #: P < 0.05 LV-siRNAs vs LV-GFP groups. ANOVA followed by Tukey's HSD post-hoc test.
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compared to the saline treated rats. As shown in panel 5C,
expression of c-Fos positive nuclei induced by amphetamine chal-
lenge was signiﬁcantly lower in the NAc shell of the LV-siRNAs shell
rats (9.6 ± 1.6) compared to the respective LV-GFP shell control
group (25.7 ± 3.5; P < 0.05, Tukey's HSD post-hoc test), while such
increase was similar in the NAc core for both the LV-siRNAs and LV-
GFP shell rats. Accordingly, as shown in Fig. 5D, lower levels of c-Fos
activation were seen in the NAc core of the LV-siRNAs core rats
(13.7 ± 0.4) compared to the LV-GFP core controls (23.8 ± 1.7;
P < 0.05, Tukey's HSD post-hoc test).
3.2. Experiment II
Since in some subjects of Experiment I a reduction of D1-IR was
observed in regions outside shell or core boundaries, in order to
reduce spreading of LV particles outside the NAc shell and core
target regions, a second experiment was performed with two
bilateral infusions of 2 ml each at a rostrocaudal distance of 500 mm.
3.2.1. Cocaine self-administration
A total of 28 rats were bilaterally inoculated with a double in-
jection of lentiviral vectors in the NAc shell or core compartments
and trained to acquire 1-h daily i.v. cocaine SA (unit dose 0.25 mg/
kg, 5 day/week), for 15 sessions under FR-1 and 18 sessions under
FR-5 schedules of responding, followed by 7 sessions of extinction
(saline, 24 ml/infusion).
3.2.1.1. Responding. Fig. 6 shows cumulative active and inactive
nose-pokes during each i.v. cocaine SA session (unit dose 0.25 mg/
kg 1-h daily, 5 days/week) by the LV-siRNAs shell, LV-GFP shell, LV-
siRNAs core and LV-GFP core groups, recorded during the FR-1
(1ste15th sessions) and FR-5 (16the33rd sessions) cocaine SA
and extinction (under FR-5, 34the40th sessions).
The FR-5 schedule of responding was extended (18 sessions), in
order to establish if longer cocaine SA exposure could reduce the
behavioral differences observed in Experiment I between the LV-
siRNAs shell and LV-GFP shell rats; however, even with a longer
maintenance period, the NAc shellDrd1a silenced group (LV-siRNAs
shell) showed reduced responding compared to the LV-GFP shell
control group, while D1aR knock-down in the NAc core (LV-siRNAs
core) once again did not affect behavior compared to the control
rats (LV-GFP core).
Four-way ANOVA applied to nose-poke, group, area and session
factors showed a main effect of nose-pokes (active vs inactive;
F1,32 ¼ 129.23, P ¼ 0.000001) and session (F39,1248 ¼ 31.61,
P ¼ 0.000001), and signiﬁcant group  area (F1,32 ¼ 5.55, P ¼ 0.02),
group  nose pokes (F1,32 ¼ 5.03, P ¼ 0.03), group  session
(F39,1248¼ 2.80, P¼ 0.000001), nose pokes session (F39,1248¼ 29.30,
P ¼ 0.000001), group  area  nose pokes (F1,32 ¼ 6.75, P ¼ 0.01),
group  area  session (F39,1248 ¼ 4.44, P ¼ 0.000001), group  nose
pokes  session (F39,1248 ¼ 2.37, P ¼ 0.00006), area  nose
pokes  session (F39,1248 ¼ 1.49, P ¼ 0.03) and group  area  nose-
pokes  session (F39,1248 ¼ 4.90, P ¼ 0.000001) interactions.
As shown in Fig. 6, the LV-GFP shell (panel A) and all the core
groups (panel B) acquired cocaine SA under FR-1 schedule during
the second week and increased active nose-poking behavior
starting from the 16th session under FR-5 schedule of responding
(P < 0.05 for active nose pokes compared to inactive ones, Tukey's
HSD post-hoc test). On the other hand, active nose-pokes emitted
by LV-siRNAs shell rats were not signiﬁcantly higher compared to
inactive ones, even during the extinction phase, in which there is
usually a tendency to observe a further increase in nose poking
Fig. 6. Experiment II: Cumulative responses and drug intake during intravenous cocaine self-administration and extinction. Cumulative responses (A and B): results are expressed
as mean ± SEM of cumulative active (ﬁlled symbols) and inactive (open symbols) nose-pokes performed by LV-GFP shell (circles) and LV-siRNAs shell (triangles) groups (panel A),
and by LV-GFP core (squares) and LV-siRNAs core (rhombus) groups (panel B), under FR-1 (1ste15th sessions) and FR-5 (16the33rd sessions) 1-h daily i.v. SA of cocaine (0.25 mg/
kg), or saline (24 ml per bolus) during extinction phase (FR-5, 34the40th sessions). N ¼ 5 rats for each group. *: P < 0.05 vs respective inactive nose-pokes [i.e., LV-GFP shell:
16the33rd sessions (panel A); LV-GFP core and LV-siRNAs core: 16the33rd sessions (panel B)]. : P < 0.05 LV-GFP shell vs LV-siRNAs shell rats. ANOVA followed by Tukey's HSD
post-hoc test. Drug intake (C and D): Intake data are expressed as mg/kg of cocaine, self-administered during sessions (ﬁlled symbols: 1ste33rd sessions), as indicated on left Y-axis,
as well as number of cocaine (ﬁlled symbols: 1ste33rd sessions) or saline (open symbols: 34the40th days) injections received during each SA phases, as indicated on the right Y-
axis. LV-GFP shell rats (circles) and LV-siRNAs shell rats (triangles) are shown in panel C; LV-GFP core rats (squares) and LV-siRNAs core rats (rhombs) are shown in panel D, n ¼ 5
rats for each group. *: P < 0.05 vs session 1 within group; ANOVA followed by Fisher's LSD post-hoc test.
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activity. Moreover, Tukey's HSD post-hoc test showed higher active
nose poking activity (P < 0.05) of the LV-GFP shell group under FR-5
schedule (16the33rd sessions) compared to the LV-siRNAs shell
rats (Fig. 6A). Conversely, the LV-siRNAs core rats showed behav-
ioral responses similar to those performed by the LV-GFP core
group, in all phases of i.v. cocaine SA (Fig. 6B).
3.2.1.2. Cocaine intake. Three-way ANOVA applied to daily in-
fusions (cocaine or saline) showed a main effect of session
(F39,624 ¼ 10.92, P ¼ 0.000001) and group  area (F1,16 ¼ 7.14,
P ¼ 0.02), group  session (F39,624 ¼ 1.79, P ¼ 0.003) and
group  area  session (F39,624 ¼ 2.73, P ¼ 0.000001) interactions.
As shown in Fig. 6, daily infusions and cocaine intake increased
in the LV-GFP shell group (Fig. 6C, P < 0.05 on 6the33rd sessions
compared to 1st week, Fisher's LSD post-hoc test) but not in the LV-
siRNAs shell rats. As in Experiment I, the LV-siRNAs core rats
showed a pattern of daily infusions not different from the LV-GFP
core rats (Fig. 6D). Three-way ANOVA applied to cocaine intake,
calculated as weekly means, showed a main effect for group
(F1,16 ¼ 5.43, P ¼ 0.03), for week (F6,96 ¼ 10.60, P ¼ 0.000001) and
group  area interactions (F1,16 ¼ 8.17 P ¼ 0.01). Post-hoc analysis
indicated an increase in cocaine intake over the weeks in all
experimental groups, except for LV-siRNAs shell rats (Table 2).
3.2.2. Immunohistochemistry
3.2.2.1. GFP expression. In vivo transfection, as indicated by GFP
expression, affected an area of about 150e200 mmof radius for each
2-ml inoculation (Fig. 3, panels C and D).
3.2.2.2. TH expression. As shown in Fig. 7 (panels A1-A4) the
integrity of the presynaptic dopaminergic ﬁbers in the NAc core and
shell was preserved, except for a slight scar along the track of the
injection cannula.
3.2.2.3. D1aR and c-Fos expression. D1-IR and c-Fos-IR in the NAc
shell and core of representative rats from the Experiment II are
shown in Fig. 7. Column B shows D1-IR, column C shows the pattern
of distribution of nuclear c-Fos-IR, while columns D and E are 20
magniﬁcations of c-Fos-IR of the selected rectangular regions
indicated in column C, relative to dorsal core and medial shell
respectively. Similar to Experiment I, c-Fos expression was reduced
in the inoculated area for both the LV-siRNAs groups compared to
the respective LV-GFP controls. Moreover, the same inoculated
areas of LV-siRNAs rats were characterized by a decreased D1-IR, as
illustrated in column B.
Fig. 8 shows percentage changes of D1-IR in inoculated areas.
Values from the two bilateral sites of vector inoculation were
averaged for each subject. Three-way ANOVA with group, area and
ROI as factors showed a main effect of group (F1,32 ¼ 44.05,
P ¼ 0.000001) and an interaction of area  ROI (F1,32 ¼ 42.98,
P¼ 0.000001) and group area ROI (F1,32¼ 39.75, P¼ 0.000001).
As shown in panel 8A, D1-IR was signiﬁcantly reduced in the NAc
shell of LV-siRNAs shell rats (78.4% ± 3.6) compared to the
respective LV-GFP shell control group (105.6% ± 3.4; P < 0.05,
Tukey's HSD post-hoc test), while no changes were found in the NAc
core in both the LV-siRNAs and LV-GFP shell rats. Accordingly, as
shown in Fig. 8B, D1-IR was signiﬁcantly reduced in the NAc core of
the LV-siRNAs core rats (79.4% ± 3.5) compared to the respective
LV-GFP core control group (109.5% ± 2.4; P < 0.05, Tukey's HSD
post-hoc test), while no changes were found in the NAc shell in both
the LV-siRNAs and LV-GFP core rats.
Fig. 8 also shows changes in expression of c-Fos positive nuclei,
induced by amphetamine challenge (5 mg/kg, s.c.), measured in the
inoculated areas of NAc shell and core of each experimental group.
Three-way ANOVA among group, area and ROI factors showed main
effect of group (F1,32 ¼ 36.06, P ¼ 0.000001) factor on c-Fos
expression. Furthermore there were signiﬁcant area  ROI
(F1,32 ¼ 42.88, P ¼ 0.000001) and group  area  ROI (F1,32 ¼ 21.52,
P¼ 0.00004) interactions. Fig. 8C shows how levels of expression of
c-Fos positive nuclei induced by amphetamine challenge were
signiﬁcantly lower in the NAc shell of LV-siRNAs shell rats (9.5 ± 1.1)
compared to the respective LV-GFP shell control group (23.2 ± 1.5;
P < 0.05, Tukey's HSD post-hoc test), while such increase was
similar in the NAc core for both the LV-siRNAs and LV-GFP shell rats.
Accordingly, as shown in Fig. 8D, lower levels of c-Fos activation
were seen in the NAc core of the LV-siRNAs core rats (10.9 ± 1.4) as
compared to the LV-GFP core controls (21.9 ± 1.1; P < 0.05, Tukey's
HSD post-hoc test).
3.3. Experiment III
3.3.1. Heroin self-administration
In Experiment III, the effect of bilateral infusion of 4 ml of len-
tiviral vectors in the NAc shell (LV-siRNAs shell and LV-GFP shell
groups) on i.v. heroin SA was evaluated. Rats were trained to ac-
quire 1-h daily i.v. heroin SA (unit dose 0.05 mg/kg, 5 day/week)
under FR-1 then switched to FR-5 schedules of responding, fol-
lowed by extinction (saline, 0.48 ml/infusion; FR-5).
3.3.1.1. Responding. Fig. 9A shows cumulative active and inactive
nose-pokes performed by the LV-GFP and LV-siRNAs groups during
FR-1 (1ste10th sessions) and FR-5 (11ste25th sessions) heroin SA
as well as the extinction (26the35th sessions, FR-5) phase.
Three-way ANOVA with nose-pokes (active and inactive), group
(LV-GFP and LV-siRNAs) and session (days) as factors, showed a
main effect of nose-pokes (active vs inactive; F1,34 ¼ 148.89,
P ¼ 0.000001) and session (F34,1156 ¼ 32.14, P ¼ 0.000001) and
interaction of nose-poke  session (F34,1156 ¼ 14.92, P ¼ 0.000001),
but not of group (F1,34 ¼ 0.02, P ¼ 0.88, N.S.), group  session
(F34,1156 ¼ 1.26, P ¼ 0.14, N.S.) and group  nose-poking  session
(F34,1156 ¼ 0.76, P ¼ 0.84, N.S.) interactions. Both the LV-GFP and LV-
siRNAs groups acquired heroin SA behavior under FR-1 schedule
during the second week and further increased active nose poking
under FR-5 (P < 0.05 active vs inactive nose-pokes, Tukey's HSD
post-hoc test). Under extinction, substitution of heroin with saline
induced an increase of responding during the 1st day followed by a
progressive decrease in both experimental groups (Fig. 9A).
Thus, infusion of LV-siRNAs in the NAc shell did not affect heroin
SA behavior compared to the LV-GFP shell rats.
Table 2
Experiment II. Mean ± SEM of weekly cocaine intake per session (mg/kg) in LV-GFP
and LV-siRNAs shell and core groups under FR-1 (1ste3rd week) and FR-5 (4the7th
week) i.v. cocaine SA. N ¼ 5 rats per group.*: P < 0.05 vs 1st week; : P < 0.05 vs
respective GFP control group. ANOVA followed by LSD's post-hoc test.
SA phases: Groups:
LV-GFP
shell
LV-siRNAs
shell
LV-GFP
core
LV-siRNAs
core
FR-1
1st week 2.5 ± 0.3 1.3 ± 0.3 1.8 ± 0.4 2.6 ± 0.7
2nd week 7.0 ± 1.6* 2.7 ± 1.4 6.1 ± 1.2* 5.7 ± 1.8*
3rd week 7.0 ± 1.1* 3.0 ± 1.6 5.3 ± 0.9* 5.7 ± 0.9*
FR-5
4th week 6.9 ± 1.6* 2.4 ± 1.2 5.3 ± 0.7* 6.4 ± 0.7*
5th week 6.9 ± 1.5* 2.0 ± 0.6 6.1 ± 0.7* 6.5 ± 0.7*
6th week 7.4 ± 2.0* 2.2 ± 0.6 5.8 ± 1.0* 7.2 ± 0.4*
7th week 9.0 ± 2.5* 2.0 ± 0.6 5.9 ± 0.6* 6.0 ± 1.0*
*: P < 0.05 vs 1st week.
: < 0.05 vs respective GFP control group.
9
ht
tp
://
do
c.
re
ro
.c
h
3.3.1.2. Heroin intake. Two-way ANOVA, among group and session
factors, applied to the daily infusions of heroin (acquisition and
maintenance) or saline (extinction) showed main effect of session
(F34,578 ¼ 9.85, P ¼ 0.000001) but not group  session (F34,578 ¼ 1.18,
P ¼ 0.23, N.S.) interaction.
Fig. 9B shows the number of heroin infusions in the LV-GFP and
LV-siRNAs rats; during the 1st day of extinction saline injections
signiﬁcantly increased in both groups.
On the other hand, two-way ANOVA applied to heroin intake
expressed as weekly means, showed a main effect of week
(F4,68 ¼ 3.93, P ¼ 0.01), and an increase of heroin intake during the
2nd and the 4th weeks in the LV-siRNAs but not in the LV-GFP rats,
and a slight but non-signiﬁcant reduction during the 3rd week in
both experimental groups (Table 3).
3.3.2. Immunohistochemistry
3.3.2.1. GFP expression. As observed in Experiment I, in vivo
transfection, indicated by GFP expression, affected an area of about
350 mm of radius around the site of inoculation of 4 ml of LV-GFP
(Fig. 3, panels E and F).
3.3.2.2. D1aR and c-Fos expression. D1aR and c-Fos immunoreac-
tivity in the NAc shell of representative rats from the Experiment III
are shown in Fig. 10. Column A shows D1-IR, column B represents
the pattern of nuclear c-Fos-IR distribution, while column C shows
20 magniﬁcations of c-Fos-IR of the selected rectangular regions
indicated in column B, relative to the medial shell. c-Fos expression
was reduced in the inoculated area of the LV-siRNAs treated ani-
mals compared to the respective LV-GFP controls. Moreover, the
same inoculated area of LV-siRNAs rats was characterized by a
decreased D1-IR, as illustrated in column A.
Fig. 11 shows percentage changes of D1-IR in inoculated areas.
D1-IR was reduced in the NAc shell of the LV-siRNAs shell rats
(73.5%± 6.9) compared to the respective LV-GFP shell control group
(102.3% ± 2.0, One-way ANOVA: F1,17 ¼ 17.65, P ¼ 0.000001;
Fig. 11A). Accordingly, as shown in Fig. 11B, expression of c-Fos
positive nuclei induced by amphetamine in the inoculated areawas
lower in the NAc shell of the LV-siRNAs rats (9.6 ± 1.5) compared to
the LV-GFP control group (18.6 ± 1.7; one-way ANOVA: F1,17¼ 15.01,
P ¼ 0.000001).
4. Discussion
The aim of the present study was to investigate the role of D1aR
in cocaine reinforcement as estimated by acquisition of i.v. cocaine
SA in rats. In order to selectively silence D1aR expression in the two
main subdivisions of the NAc, the shell and the core, lentiviral
vectors expressing Drd1a-siRNAwere stereotaxically infused in the
medial shell and in the dorsal core of the NAc of different groups of
rats.
Two different procedures were used. In Experiment I, 4 ml of
viral stock solution were infused bilaterally into a single site in the
NAc shell or core, while in Experiment II, the 4-ml stock solutionwas
split in two 2-ml aliquots that were infused bilaterally into two
different sitesz500 mm apart in the NAc shell or core. This second
procedure was chosen in an attempt to improve the site speciﬁcity
of silencing by restricting it to each NAc subdivision. In fact, his-
tological analysis of Experiment I had shown that infusion of 4 ml of
Fig. 7. Experiment II: TH, D1aR and c-Fos expression in the NAc of LV-siRNAs and LV-GFP inoculated rats. Columns A, B and C show respectively TH and D1aR immunoreactivity and
pattern of induction of nuclear c-Fos immunoreactivity, in representative LV-GFP shell (row 1), LV-siRNAs shell (row 2), LV-GFP core (row 3) and LV-siRNAs core (row 4) rats.
Microphotographs were acquired by a Nikon Cool Scan 9000ED with a scanning resolution of 4000 dpi, scale bar is 500 mm. Columns D and E show magniﬁcations (20) of c-Fos
immunoreactivity of dorsal core (D) and medial shell (E) in the regions of interest (rectangles) represented in column C. Microphotographs have been acquired by a Zeiss Axi-
oScopeA1 microscope with a 20 magniﬁcation objective, scale bar is 100 mm.
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viral solution into the medial shell resulted in transfection to the
adjacent aspects of the core and olfactory tubercle, instead of just
being conﬁned to the medial shell. Histological analysis of Experi-
ment II showed that, indeed, the area transfected (z150 mm radius)
was well within the NAc shell boundaries.
Stimulation of dopamine transmission by psychostimulants in-
duces dose-dependent expression of c-Fos in rat striatum
(Brenhouse and Stellar, 2006; Graybiel et al., 1990). This effect is
abolished by pretreatment with the D1R antagonist SHC 23390,
(Graybiel et al., 1990) and is lost in D1 KO mice (Moratalla et al.,
1996). Therefore, stimulation of c-Fos expression by psychostimu-
lants is mediated by stimulation of D1aR. In view of this, c-Fos
expression in the NAc shell and core regions induced by amphet-
amine challenge, was utilized as an estimate of D1aR function. The
density of c-Fos positive nuclei was reduced in the shell compart-
ment in LV-siRNAs shell groups in Experiments I, II and III, and in
the core compartment of LV-siRNAs core groups in Experiment I
and II.
The persistence of a residual D1aR responsiveness might explain
the SA behavior recorded in LV-siRNAs shell group in Experiment I.
However, in this experiment rats showed a delayed acquisition, a
lower active nose poking activity, and a reduced cocaine intake,
compared to LV-GFP shell control rats. On the other hand, in
Experiment II, in which the total volume of 4 ml was infused into
two sites along the rostro-caudal axis, rats did not acquire cocaine
SA, as signiﬁcant differences between active and inactive nose-
pokes were not reached, neither under FR-1 nor under FR-5
schedule of responding. Infusion of control GFP-expressing vec-
tors in the NAc shell did not affect acquisition. On the other hand,
silencing of D1aR expression in the NAc core did not affect acqui-
sition of responding for i.v. cocaine. In both experiments, the group
infused with LV-siRNAs for D1aR in the shell showed a reduction of
responding for cocaine and of cocaine intake compared to controls,
while infusion of the same LV-Drd1a-siRNAs in the NAc core did not
affect responding for cocaine. Therefore, only D1aR silencing in the
NAc shell was able to impair acquisition of responding for i.v.
cocaine SA, indicating that DA D1aRs in the NAc shell, but not in the
core, are important for acquisition of cocaine reinforcement.
Silencing of NAc shell D1aR expression by infusion of LV-siRNA in
the NAc shell using a protocol similar to that utilized in Experiment
I, failed to affect acquisition of heroin i.v. SA. This observation,
consistent with previous studies on the effect of DA receptor an-
tagonists on the acquisition of heroin SA (Ettenberg et al., 1982),
excludes the possibility that impairment of cocaine SA induced by
Fig. 8. Experiment II: Bar charts representing changes in D1aR immunoreactivity and c-Fos expression in the Nac shell and core of LV-GFP and LV-siRNAs inoculated rats. Panels A
and B show optical density (OD) of D1-IR in the inoculated regions, expressed as percentage of the overall OD of corresponding shell or core areas. Values are expressed as
means ± SEM of %OD. Panels C and D show counts of c-Fos-positive nuclei/ﬁeld in the inoculated regions, in amphetamine (5 mg/kg) challenged rats. Values are expressed as
means ± SEM of positive nuclei/ﬁeld. #: P < 0.05 LV-siRNAs vs LV-GFP groups. ANOVA followed by Tukey's HSD post-hoc test.
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silencing of NAc shell DA D1aR is due to a general impairment of
instrumental learning or motivation. Collectively therefore, the
impairment of cocaine self-administration, elicited by silencing of
D1aR expression in the NAc shell, can be interpreted as due to a
devaluation of the reinforcing properties of cocaine.
Previous studies comparing the role of NAc shell and core DA in
cocaine reinforcement have obtained contrasting results. Bari and
Pierce (2005) reported that both intra-shell and intra-core infu-
sion of D1 (SCH23390) and D2 (eticlopride) receptor antagonists
reduce the breaking point in a progressive ratio schedule of i.v.
cocaine self-administration. However, D1 and D2 antagonists also
reduced food reinforcement when infused in the NAc core, while
they did not affect it after infusion in the shell. Therefore, it was
concluded that blockade of DA receptors in the NAc core impaired
cocaine reinforcement by a general impairment of motivation.
The possibility that blockade of DA receptors in the NAc core by
local DA antagonists impairs cocaine reinforcement, due to an ef-
fect on motivation, is also suggested by Di Ciano (2008), who re-
ported that infusion of ﬂupentixol in the core and in the medio-
dorsal part of the shell reduced responding for cocaine on a
second-order schedule of i.v. self-administration. In contrast, on an
FR-1 schedule ﬂupentixol increased responding when infused in
the shell while decreased it after infusion in the core. These ob-
servations were interpreted to indicate that DA in the NAc shell,
rather than in the core, mediates cocaine reward (Di Ciano, 2008).
Recently, Veeneman et al. (2012) reported that the infusion of
ﬂupentixol in the portion of the shell just ventral to the core, de-
creases FR-1 responding for i.v. cocaine self-administration, as well
as sucrose reinforcement, and attributed these effects to an
impairment of motivation. Infusion of ﬂupentixol into the core had
no effect. The observations of Veeneman et al. (2012) are at odds
with those of Bari and Pierce (2005) (no effect of intra-shell DA
antagonists on food reinforcement) and with those of Bachtell et al.
(2005) and Di Ciano (2008) (increase in responding for i.v. cocaine
after intra-shell DA antagonists). Indeed, Veeneman et al. (2012)
attributed to NAc shell DA the motivational role that Bari and
Pierce (2005) and Di Ciano (2008) attributed to NAc core DA. It is
notable however, that in the study of Veeneman et al. (2012), in
order to infuse ﬂupentixol in the ventro-medial shell, cannulas
went through the dorsally located core, while in the studies of Bari
and Pierce (2005), Bachtell et al. (2005) and Di Ciano (2008), as well
as in the present study, the medio-dorsal part of the shell was
targeted, thus sparing the core. In order to explain the above dis-
crepancies, one might consider that in the study of Veeneman et al.
(2012), ﬂupentixol may have reached the dorsally located core by
leakage of the ﬂuid along the track that the cannula left in the core
on its way to the shell. In view of this, and of the fact that food (Bari
and Pierce, 2005) or heroin reinforcement (Alderson et al., 2001
and present study) were not affected by excitotoxic lesions of the
shell (Alderson et al., 2001), as well as more medial intra-shell
placements of D1 antagonists (Bari and Pierce, 2005) and of LV-
Drd1a-siRNAs (present study) that spare the core, we suggest that
the effect of the intra-shell ﬂupentixol on cocaine and food rein-
forcement reported by Veeneman et al. (2012) could be due to
blockade of DA receptors of the core. Viewed from this perspective,
the results of Veeneman et al. (2012) can be reconciled with those
of previous studies and of the present one. Veeneman et al. (2012)
also reported that intra-shell infusion of ﬂupentixol at the begin-
ning of each of the 5 trials impairs acquisition of cocaine self-
administration. However, as soon as ﬂupentixol was discontinued
responding increased to the levels of controls. On this basis, it was
suggested that the drug had not impaired acquisition but
responding itself. This effect, however, may have originated from
the core rather than the shell (see above).
In relation to the main issue of the present study, i.e. to clarify
the relative role of NAc shell and core DA D1aR in cocaine rein-
forcement, the use of LV-RNAi approach to impair receptor function
shows two main advantages over local intracerebral infusion of
speciﬁc receptor antagonists. The ﬁrst advantage is that LV-RNAi
can be applied to chronic behavioral paradigms, in which the
repeated intracerebral infusion of highly lipophilic drugs would
result in drug diffusion to large brain areas, if not to the whole
Fig. 9. Experiment III: Cumulative responses and drug intake during intravenous heroin self-administration and extinction. Panel A shows LV-GFP shell (circles, n ¼ 10) and LV-
siRNAs shell (triangles, n ¼ 9) rats under FR-1 (1ste10th sessions) and FR-5 (11ste25th sessions) 1-h daily i.v. heroin SA (0.05 mg/kg), or saline (48 ml per bolo) during extinc-
tion phase (FR-5, 26the35th sessions). Results are expressed as mean ± SEM of cumulative active (ﬁlled symbols) and inactive (open symbols) nose-pokes performed by each
experimental group. *: P < 0.05 vs LV-siRNAs inactive nose-pokes; #: P < 0.05 vs LV-GFP inactive nose-pokes (ANOVA followed by Tukey's HSD post-hoc test). Panel B shows daily
heroin intake and number of infusions during heroin self-administration and extinction in LV-GFP shell (circles, n ¼ 10) and LV-siRNAs shell (triangles, n ¼ 9) rats during each 1-h
daily SA sessions. FR-1 and FR-5 operative schedules are also indicated. Intake data from each group are expressed as mg/kg of heroin, self-administered during sessions (ﬁlled
symbols, 1ste25th sessions) as indicated on left Y-axis, as well as number of heroin (ﬁlled symbols, 1ste25th sessions) or saline (open symbols: 26the35th days) injections during
each SA phases, as indicated on the right Y-axis. *: P < 0.05 vs LV-siRNAs last day of heroin SA; #: P < 0.05 vs LV-GFP last day of heroin SA. ANOVA followed by Tukey's HSD post-hoc
test.
Table 3
Experiment III. Mean ± SEM of weekly heroin intake per session (mg/kg) in LV-GFP
(N ¼ 9) and LV-siRNAs (N ¼ 10) groups under FR-1 (1ste2nd week) and FR-5
(3rde5th week) i.v. heroin SA.*: P < 0.05 vs 1st week. ANOVA followed by LSD's
post-hoc test.
SA phases: Groups:
LV-GFP shell LV-siRNAs shell
FR-1
1st week 0.33 ± 0.03 0.32 ± 0.02
2nd week 0.36 ± 0.03 0.48 ± 0.05*
FR-5
3rd week 0.31 ± 0.03 0.31 ± 0.04
4th week 0.30 ± 0.04 0.44 ± 0.07*
5th week 0.37 ± 0.03 0.41 ± 0.05
*: P < 0.05 vs 1st week.
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brain, with consequent loss of site speciﬁcity. A second advantage
of LV-RNAi is that the distribution and degree of functional
impairment can be precisely determined, while this is unfeasible in
the case of competitive receptor ligands. Therefore, by using LV-
siRNA for D1aR, the present study provides experimental evi-
dence that DA D1aRs in the NAc shell rather than those in the core
are essential for cocaine reinforcement.
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